Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists

키워드

참고문헌 (70)

1. 박성우, "Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 1. Introduction", Tuberculosis and Respiratory Diseases, 82(4), pp.269~276 (2019), 대한결핵및호흡기학회[DOI]
2. Kinder BW, "Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?", Am J Respir Crit Care Med, 176, pp.691~697 (2007)
3. Fischer A, "An official European Respiratory Society", American Thoracic Society research statement : interstitial pneumonia with autoimmune features, 2015, pp.46, 976~987
4. Fischer A, "Connective tissue disease-associated interstitial lung disease : a call for clarification", Chest, 138, pp.251~256 (2010)
5. Vij R, "Autoimmune-featured interstitial lung disease : a distinct entity", Chest, 140, pp.1292~1299 (2011)
6. Corte TJ, "Significance of connective tissue disease features in idiopathic interstitial pneumonia", Eur Respir J, 39, pp.661~668 (2012)
7. Oldham JM, "Characterisation of patients with interstitial pneumonia with autoimmune features", Eur Respir J, 47, pp.1767~1775 (2016)
8. Ahmad K, "Interstitial pneumonia with autoimmune features : clinical, radiologic, and histological characteristics and outcome in a series of 57 patients", Respir Med, 123, pp.56~62 (2017)
9. Lim JU, "Interstitial pneumonia with autoimmune features show better survival and less exacerbations compared to idiopathic pulmonary fibrosis", BMC Pulm Med, 19, pp.120~ (2019)
10. Sambataro G, "Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features(IPAF)patients", Respir Med, 150, pp.154~160 (2019)
11. Ito Y, "Serological and morphological prognostic factors in patients with interstitial pneumonia with autoimmune features", BMC Pulm Med, 17, pp.111~ (2017)
12. Kim HC, "Long-term clinical course and outcome of interstitial pneumonia with autoimmune features", Respirology, 25, pp.636~643 (2020)
13. Chartrand S, "Clinical characteristics and natural history of autoimmune forms of interstitial lung disease : a single-center experience", Lung, 197, pp.709~713 (2019)
14. Dai J, "Clinical features, risk factors, and outcomes of patients with interstitial pneumonia with autoimmune features : a population-based study", Clin Rheumatol, 37, pp.2125~2132 (2018)
15. Chartrand S, "Clinical features and natural history of interstitial pneumonia with autoimmune features : a single center experience", Respir Med, 119, pp.150~154 (2016)
16. Sebastiani M, "Interstitial pneumonia with autoimmune features : a single center prospective follow-up study", Autoimmun Rev, 19, pp.102451~ (2020)
17. Yoshimura K, "Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia", Respir Med, 137, pp.167~175 (2018)
18. Tirelli C, "Multidisciplinary approach in the early detection of undiagnosed connective tissue diseases in patients with interstitial lung disease: a retrospective cohort study", Front Med(Lausanne), 7, pp.11~ (2020)
19. Tian M, "Comparative analysis of connective tissue disease-associated interstitial lung disease and interstitial pneumonia with autoimmune features", Clin Rheumatol, 39, pp.575~583 (2020)
20. Collins BF, "Idiopathic interstitial pneumonia associated with autoantibodies : a large case series followed over 1 year", Chest, 152, pp.103~112 (2017)
21. Alevizos MK, "Risk of progression of interstitial pneumonia with autoimmune features to a systemic autoimmune rheumatic disease", Rheumatology(Oxford), 59, pp.1233~1240 (2020)
22. Schurawitzki H, "Interstitial lung disease in progressive systemic sclerosis : high-resolution CT versus radiography", Radiology, 176, pp.755~759 (1990)
23. Tashkin DP, "Cyclophosphamide versus placebo in scleroderma lung disease", N Engl J Med, 354, pp.2655~2666 (2006)
24. Sanchez-Cano D, "Interstitial lung disease in systemic sclerosis : data from the Spanish scleroderma study group", Rheumatol Int, 38, pp.363~374 (2018)
25. Fathi M, "Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis", Ann Rheum Dis, 63, pp.297~301 (2004)
26. Chen IJ, "Interstitial lung disease in polymyositis and dermatomyositis", Clin Rheumatol, 28, pp.639~646 (2009)
27. Hayashi S, "High-resolution computed tomography characterization of interstitial lung diseases in polymyositis", dermatomyositis, 2008, pp.35, 260~269
28. Bongartz T, "Incidence and mortality of interstitial lung disease in rheumatoid arthritis : a population-based study", Arthritis Rheum, 62, pp.1583~1591 (2010)
29. Gochuico BR, "Progressive preclinical interstitial lung disease in rheumatoid arthritis", Arch Intern Med, 168, pp.159~166 (2008)
30. Guisado-Vasco P, "Quantitative assessment of interstitial lung disease in Sjögren’s syndrome", PLoS One, 14, pp.e0224772~ (2019)
31. Roca F, "Interstitial lung disease in primary Sjögren’s syndrome", Autoimmun Rev, 16, pp.48~54 (2017)
32. Dong X, "A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population", Clin Rheumatol, 37, pp.2981~2988 (2018)
33. Damoiseaux J, "Clinical relevance of HEp-2 indirect immunofluorescent patterns : the International Consensus on ANA patterns(ICAP)perspective", Ann Rheum Dis, 78, pp.879~889 (2019)
34. Cottin V, "Interstitial lung disease associated with systemic sclerosis(SSc-ILD)", Respir Res, 20, pp.13~ (2019)
35. Koenig M, "Predictive value of antinuclear autoantibodies : the lessons of the systemic sclerosis autoantibodies", Autoimmun Rev, 7, pp.588~593 (2008)
36. Spagnolo P, "Genetics of idiopathic pulmonary fibrosis : from mechanistic pathways to personalised medicine", J Med Genet, 54, pp.93~99 (2017)
37. McLean-Tooke A, "Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges", Clin Transl Immunology, 8, pp.e1086~ (2019)
38. Newton CA, "Telomere length and genetic variant associations with interstitial lung disease progression and survival", Eur Respir J, 53, pp.1801641~ (2019)
39. Linn-Rasker SP, "Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLADRB1 shared epitope alleles", Ann Rheum Dis, 65, pp.366~371 (2006)
40. Lee HS, "Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide : a mixed picture in three large North American rheumatoid arthritis cohorts", Arthritis Rheum, 56, pp.1745~1753 (2007)
41. Schiffenbauer A, "The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis", Semin Arthritis Rheum, 48, pp.504~512 (2018)
42. Karabulut G, "Cigarette smoking in primary Sjögren’s syndrome : positive association only with ANA positivity", Mod Rheumatol, 21, pp.602~607 (2011)
43. Kang J, "Exacerbation of symptomatic arthritis by cigarette smoke in experimental arthritis", PLoS One, 15, pp.e0230719~ (2020)
44. Aletaha D, "2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2010, pp.62, 2569~2581
45. van den Hoogen F, "2013 Classification criteria for systemic sclerosis : an American College of Rheumatology", European League against Rheumatism collaborative initiative, 2013, pp.65, 2737~2747
46. Sulli A, "Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients", Ann Rheum Dis, 67, pp.885~887 (2008)
47. Shiboski CH, "2016 American College of Rheumatology", European League against Rheumatism Classification criteria for primary Sjögren’s syndrome : a consensus and data-driven methodology involving three international patient cohorts, 2017, pp.69, 35~45
48. Aringer M, "2019 European League against Rheumatism", American College of Rheumatology classification criteria for systemic lupus erythematosus, 2019, pp.71, 1400~1412
49. Dalakas MC, "Inflammatory muscle diseases", N Engl J Med, 372, pp.1734~1747 (2015)
50. Alba MA, "Interstital lung disease in ANCA vasculitis", Autoimmun Rev, 16, pp.722~729 (2017)
51. Castelino FV, "Interstitial lung disease in connective tissue diseases : evolving concepts of pathogenesis and management", Arthritis Res Ther, 12, pp.213~ (2010)
52. Gao Y, "Treatment of the connective tissue disease-related interstitial lung diseases : a narrative review", Mayo Clin Proc, 95, pp.554~573 (2020)
53. Li Y, "IPAF should receive early treatment for sharing similar clinical characteristics as CTD-ILD : a report from 273 Chinese patients", Clin Rheumatol, 39, pp.3817~3823 (2020)
54. Noble PW, "Pirfenidone in patients with idiopathic pulmonary fibrosis(CAPACITY) : two randomised trials", Lancet, 377, pp.1760~1769 (2011)
55. King TE Jr, "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2083~2092 (2014)
56. Margaritopoulos GA, "Pirfenidone improves survival in IPF : results from a real-life study", BMC Pulm Med, 18, pp.177~ (2018)
57. Richeldi L, "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2071~2082 (2014)
58. Lancaster L, "Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib : pooled data from six clinical trials", BMJ Open Respir Res, 6, pp.e000397~ (2019)
59. Acharya N, "Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial", Rheumatol Int, 40, pp.703~710 (2020)
60. Distler O, "Nintedanib for systemic sclerosis-associated interstitial lung disease", N Engl J Med, 380, pp.2518~2528 (2019)
61. Flaherty KR, "Design of the PF-ILD trial : a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease", BMJ Open Respir Res, 4, pp.e000212~ (2017)
62. Maher TM, "Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease : design of a double-blind, randomised, placebo-controlled phase II trial", BMJ Open Respir Res, 5, pp.e000289~ (2018)
63. Sambataro G, "The morphological domain does not affect the rate of progression to defined autoimmune diseases in patients with interstitial pneumonia with autoimmune features", Chest, 157, pp.238~242 (2020)
64. Bourn R, "Preclinical lupus", Curr Opin Rheumatol, 27, pp.433~439 (2015)
65. Smolen JS, "Rheumatoid arthritis", Nat Rev Dis Primers, 4, pp.18001~ (2018)
66. Hyldgaard C, "A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease : comorbidity and mortality", Ann Rheum Dis, 76, pp.1700~1706 (2017)
67. Peelen L, "Fibrotic idiopathic interstitial pneumonias : mortality is linked to a decline in gas transfer", Respirology, 15, pp.1233~1243 (2010)
68. Song JW, "Acute exacerbation of idiopathic pulmonary fibrosis : incidence, risk factors and outcome", Eur Respir J, 37, pp.356~363 (2011)
69. Leuschner G, "Acute exacerbation in interstitial lung disease", Front Med(Lausanne), 4, pp.176~ (2017)
70. Kelly BT, "Overlap of interstitial pneumonia with autoimmune features with undifferentiated connective tissue disease and contribution of UIP to mortality", Respirology, 23, pp.600~605 (2018)

관련 논문AI추천